Our Story
We aim to shift the current wound care treatment paradigm with a high impact therapeutic approach
For decades, innovation in the wound care industry has been dominated by incremental, low-risk and device-driven innovations
Only one new pharmaceutical treatment approved for use - 20 years ago
Despite this plethora of new products, healing rates have barely changed
The FDA & industry is calling for a new approach
We aim to shift the current treatment paradigm with a high impact therapeutic approach to debridement
We aim to enable dramatic improvements in healing rates and patients’ quality of life
Our Mission
Significantly improving the health and wellbeing of patients with chronic wounds
Executive Team
Andy Weymann, MD
CHAIRMAN
A surgeon by background and formerly Chief Medical Officer at Smith & Nephew, Andy brings not only deep sector experience to SolasCure, but also more than 25 years of executive and board experience in global medical device, biopharma & regenerative medicine companies to SolasCure.
Lee Harle
CHIEF EXECUTIVE OFFICER
Lee is an experienced business leader with >25 years of experience building businesses & joint-ventures in consumer goods, technology and life-science industries around the world, specialising in life-science venture building and commercialisation. Formerly Chief Business Officer at SolasCure.
David Fairlamb
Chief Development Officer
David brings vast, global knowledge of wound care development and Regulatory Affairs, with over 30 years of experience across Drug, Biologics, Medical Devices and Combination Products, including senior regulatory positions within Smith & Nephew Wound Management, Renovo plc and in consultancy at ProTherax Ltd.
Dr. Bela Kelety
CHIEF TECHNOLOGY OFFICER
Bela brings a long track record of successful R&D and technology development to Solascure with experience across multiple bioscience companies, including BRAIN AG. Bela previously co-founded a successful biotech company and has a Ph.D. in biochemistry from the Max Planck Institute.
Oliver Schofield
CHIEF FINANCIAL OFFICER
Oliver is an experienced biotech startup CFO having started his career in Management Consulting at KPMG. Oliver is a CIMA certified accountant with an MPhil in Bioscience Enterprise from the University of Cambridge.
Antoinette van Dijk, MD
DIRECTOR CLINICAL AND MEDICAL AFFAIRS
With more than 20 years of both strategic and operational experience in clinical research and development of pharmaceuticals and medical devices, Antoinette brings a deep understanding of the complexity and practicalities of global clinical development to Solascure, leveraging her experience across the CRO and Pharma industries together with a focus on methodological and ethical aspects of development.
Adam Rytko
Quality Assurance Director
Adam has over 18 years of experience in the pharmaceutical and clinical environment with emphasis in Quality Assurance and auditing. Starting as a CRA he shifted to GCP Quality area, focusing on clinical site and vendor auditing, executing approx. 200 audits. For 5 years Adam is in charge of quality systems implementation and development.
Board Of Directors
Key Medical Advisors
Transforming Chronic Wound Patient Outcomes
Empowering Clinicians with Practical, Impactful Solutions
Enhancing Efficiency & Value for Health Systems
Robert Kirsner
M.D., PhD
Key Opinion Leader
Dr. Robert Kirsner, M.D., PhD is Chairman and Harvey Blank Professor of Dermatology at the University of Miami Miller School of Medicine. He directs the University of Miami Hospital Wound Center and serves as Chief of Dermatology at University of Miami Hospital and Clinics. Dr. Kirsner earned his MD and PhD from the University of Miami and has published over 550 articles.